Company

AbbVie

Pharmaceutical intelligence for AbbVie with 14 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 7
Assets: 9

Recent signals(7)

ClinicalJune 20, 2026

AbbVie initiates trial for telisotuzumab adizutecan in mCRC with FOLFOX and bevacizumab/panitumumab

A new study is evaluating the efficacy and safety of telisotuzumab adizutecan in combination with standard mCRC treatments.

ClinicalJune 19, 2026

AbbVie Initiates Trial for ABBV-932 in Bipolar Disorder Depressive Episodes

AbbVie is conducting a trial to evaluate the safety and efficacy of ABBV-932 in adults with depressive episodes linked to bipolar I or II disorder.

ClinicalJune 19, 2026

AbbVie Evaluates XEN63 Gel Stent for Glaucoma via Two Surgical Approaches

A clinical trial is underway to assess the safety and effectiveness of the XEN63 gel stent in glaucoma patients using two different surgical approaches.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for SKYRIZI (Risankizumab)

The FDA has accepted a supplemental application for SKYRIZI, indicating ongoing development and potential label expansion.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie

The FDA has accepted a supplemental application for SKYRIZI (Risankizumab) from AbbVie.

RegulatoryJune 17, 2026

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

Quinacrine is included on the FDA 503B list for compounding, indicating a clinical need for its use in treating cutaneous lupus erythematosus.

ClinicalJune 17, 2026

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

A Phase II study is assessing the outcomes of stopping BTK inhibitor therapy in CLL patients in remission for over two years.

Upcoming catalysts(1)

Phase II Readout

AbbVie — Emraclidine

Second-wave muscarinic data will clarify class viability post-KarXT launch.

September 18, 2026 · Phase II

Regulatory activity(3)

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for SKYRIZI (Risankizumab)

The FDA has accepted a supplemental application for SKYRIZI, indicating ongoing development and potential label expansion.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie

The FDA has accepted a supplemental application for SKYRIZI (Risankizumab) from AbbVie.

RegulatoryJune 17, 2026

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

Quinacrine is included on the FDA 503B list for compounding, indicating a clinical need for its use in treating cutaneous lupus erythematosus.

Clinical activity(4)

ClinicalJune 20, 2026

Competitive activity

No signals indexed for this entity yet.

Assets

Quinacrine Hydrochloride →

SKYRIZI →

Trial Update →

XEN63 →

Therapeutic areas

Dermatology · Aesthetic Medicine →

Dermatology · Autoimmune Disease →

Neurology · Bipolar Disorder →

Ophthalmology · Glaucoma →

Indications

Autoimmune Disease →

Bipolar Disorder →

Schizophrenia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.